Please assess the completion status of the following clinical trial:

Trial Title: Online Information and Support for Distance Caregivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Patient Inclusion Criteria:~* a new diagnosis (within 3 months) of advanced cancer and/or patients receiving ongoing care from a medical oncologist (solid tumors) or a new recurrence of the primary cancer in an advanced stage~* receives ongoing care from a medical oncologist at the Seidman Cancer Center~* Has English as the primary language~* Has a life expectancy of \>6 months~* Provides consent for his/her own treatment and procedures~* Identifies a distant care giver (DCG) involved in his/her care, support or planning~Patient Exclusion Criteria:~* The patient sample is limited to patients with advanced cancer and/or patients receiving ongoing care from a medical oncologist because the full intervention is tailored to meet the needs of DCGs of patients with advanced cancer and/or patients receiving ongoing care from a medical oncologist~Caregiver Inclusion Criteria~* Is an adult family member (at least 18 years old) of a patient with an advanced-stage cancer~* Identifies himself/herself as a DCG for the patient~* Lives \>1 hour travel time away from the patient~* Has English as his/her primary language~* Is capable of providing informed consent~* Will be able to access the internet (phone, computer, etc.)~Caregiver Exclusion Criteria~* Cognitive Impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Closer (Type: EXPERIMENTAL): The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired.
- Video-C Only (Type: ACTIVE_COMPARATOR): This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose \~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG.
- Web-Only (Type: ACTIVE_COMPARATOR): This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).